Related Experiment Videos
Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target
A Verma1, S L Facchina, D J Hirsch
1Department of Neurology, Uniformed Service University of the Health Sciences, Bethesda, Maryland, USA.
Background:
Photodynamic therapy employs photosensitive agents such as porphyrins to treat a variety of tumors accessible to light-emitting probes. This approach capitalizes on the selective retention of porphyrins by cancer cells. Cancer cells also have elevated levels of mitochondrial benzodiazepine receptors which bind porphyrins with high affinity.
Methods:
Cultured cancer cell lines were exposed to porphyrin and porphyrin-like compounds and then irradiated with light. Cytotoxicity of this treatment was measured via clonogenic assays. Mitochondrial benzodiazepine receptor pharmacology was studied using [3H] PK11195 binding to cancer cell homogenates and isolated kidney mitochondrial membranes.
Results:
We show that therapeutic potencies of porphyrins correlate closely with affinities for mitochondrial benzodiazepine receptors. Sensitivities of tumor cell lines to photodynamic therapy parallel their densities of these receptors.
Conclusion:
We propose that porphyrin photodynamic therapy is mediated by mitochondrial benzodiazepine receptors.
Insights
Photodynamic therapy uses porphyrins to kill cancer cells. This study shows porphyrin effectiveness is linked to mitochondrial benzodiazepine receptors, suggesting they mediate the therapy.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Photodynamic therapy (PDT) utilizes photosensitive agents like porphyrins for tumor treatment.
- Cancer cells selectively retain porphyrins and exhibit high-affinity binding to mitochondrial benzodiazepine receptors.
- This presents a potential mechanism for targeted cancer therapy.
Purpose of the Study:
- To investigate the correlation between porphyrin binding affinity to mitochondrial benzodiazepine receptors and their therapeutic efficacy in cancer treatment.
- To explore the role of mitochondrial benzodiazepine receptors in mediating the effects of porphyrin-based photodynamic therapy.
Main Methods:
- Cancer cell lines were treated with porphyrin compounds and light, with cytotoxicity assessed by clonogenic assays.
- Mitochondrial benzodiazepine receptor pharmacology was evaluated using radioligand binding assays ([3H] PK11195).
- Binding studies were conducted on both cancer cell homogenates and isolated kidney mitochondrial membranes.
Main Results:
- A strong correlation was observed between the therapeutic potency of porphyrins and their affinity for mitochondrial benzodiazepine receptors.
- The sensitivity of different tumor cell lines to photodynamic therapy directly paralleled the density of these receptors.
- These findings indicate a direct relationship between receptor levels and treatment response.
Conclusions:
- The study proposes that mitochondrial benzodiazepine receptors play a crucial role in mediating porphyrin-based photodynamic therapy.
- This receptor-mediated mechanism could be a key factor in the selective targeting and destruction of cancer cells by PDT.
- Understanding this interaction may lead to improved strategies for photodynamic cancer treatment.